Biopsy analysis of trial S1616: Ipilimumab plus nivolumab versus ipilimumab alone in patients with anti-PD-1 refractory melanoma

被引：0
|
作者：
Campbell, Katie M.
Bustami, Zaid
Chen, Daniel G.
Medina, Egmidio
Gonzalez, Cynthia R.
Aldeen, Nataly Naser
Baselga-Carretero, Ignacio
Vega-Crespo, Agustin
Maxey, Jessica
Chen, Jia M.
Kuklinski, Lawrence F.
Kendra, Kari L.
Chmielowski, Bartosz
Thach-Giao Truong
Khushalani, Nikhil I.
Collichio, Frances
Ikeguchi, Alexandra
Victor, Adrienne I.
Margolin, Kim
Sosman, Jeffrey A.
Patel, Sapna P.
Hu-Lieskovan, Siwen
Moon, James
Bellasea, Shay
Wells, Daniel K.
Spencer, Christine N.
Thompson, Marshall A.
Wu, Michael
Scumpia, Philip O.
VanderWalde, Ari
Ribas, Antoni
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-6550
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6550
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Ipilimumab after progression on anti-PD-1 treatment in advanced melanoma
    Aya, Francisco
    Gaba, Lydia
    Victoria, Ivan
    Fernandez-Martinez, Aranzazu
    Tosca, Monica
    Prat, Aleix
    Arance, Ana
    FUTURE ONCOLOGY, 2016, 12 (23) : 2683 - 2688
  • [22] Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma
    Alden, Stephanie L.
    Lim, Mir
    Kao, Chester
    Shu, Daniel
    Singal, Amit G.
    Noonan, Anne
    Griffith, Paige
    Baretti, Marina
    Ho, Won Jin
    Kamel, Ihab
    Yarchoan, Mark
    Hsiehchen, David
    CANCER RESEARCH COMMUNICATIONS, 2023, 3 (07): : 1312 - 1317
  • [23] Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma
    Long, Georgina V.
    Larkin, James
    Schadendorf, Dirk
    Grob, Jean-Jacques
    Lao, Christopher D.
    Marquez-Rodas, Ivan
    Wagstaff, John
    Lebbe, Celeste
    Pigozzo, Jacopo
    Robert, Caroline
    Ascierto, Paolo A.
    Atkinson, Victoria
    Postow, Michael A.
    Atkins, Michael B.
    Sznol, Mario
    Callahan, Margaret K.
    Topalian, Suzanne L.
    Sosman, Jeffrey A.
    Kotapati, Srividya
    Thakkar, Pratik K.
    Ritchings, Corey
    Benito, Melanie Pe
    Re, Sandra
    Soleymani, Samira
    Hodi, F. Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (08)
  • [24] Comparative effectiveness of second-line ipilimumab vs. nivolumab in combination with ipilimumab in patients with advanced melanoma who received frontline anti-PD-1 antibodies
    Baron, Kelsey
    Moser, Justin C.
    Patel, Shiven
    Grossmann, Kenneth F.
    Colonna, Sarah, V
    Hyngstrom, John R.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2021, 27 (03) : 555 - 559
  • [25] Phase III randomized trial evaluating tilsotolimod in combination with ipilimumab versus ipilimumab alone in patients with advanced refractory melanoma (ILLUMINATE 301).
    Diab, Adi
    Ascierto, Paolo Antonio
    Abdel-Wahab, Reham
    Maio, Michele
    Negrier, Sylvie
    Mortier, Laurent
    Dalle, Stephane
    Krajsova, Ivana
    de la Cruz, Luis
    Leccia, Marie Therese
    Guida, Michele
    Lebbe, Celeste
    Grob, Jean-Jacques
    Butler, Marcus O.
    In, Gino Kim
    Chunduru, Srinivas
    Rahimian, Shah
    Robert, Caroline
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA9516 - LBA9516
  • [26] Increased Soluble PD-1 Predicts Response to Nivolumab plus Ipilimumab in Melanoma
    Pedersen, Jesper Geert
    Sokac, Mateo
    Sorensen, Boe Sandahl
    Luczak, Adam Andrzej
    Aggerholm-Pedersen, Ninna
    Birkbak, Nicolai Juul
    Ollegaard, Trine Heide
    Jakobsen, Martin Roelsgaard
    CANCERS, 2022, 14 (14)
  • [27] Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma
    da Silva, Ines Pires
    Ahmed, Tasnia
    McQuade, Jennifer L.
    Nebhan, Caroline A.
    Park, John J.
    Versluis, Judith M.
    Serra-Bellver, Patricio
    Khan, Yasir
    Slattery, Tim
    Oberoi, Honey K.
    Ugurel, Selma
    Haydu, Lauren E.
    Herbst, Rudolf
    Utikal, Jochen
    Pfoehler, Claudia
    Terheyden, Patrick
    Weichenthal, Michael
    Gutzmer, Ralf
    Mohr, Peter
    Rai, Rajat
    Smith, Jessica L.
    Scolyer, Richard A.
    Arance, Ana M.
    Pickering, Lisa
    Larkin, James
    Lorigan, Paul
    Blank, Christian U.
    Schadendorf, Dirk
    Davies, Michael A.
    Carlino, Matteo S.
    Johnson, Douglas B.
    Long, Georgina V.
    Lo, Serigne N.
    Menzies, Alexander M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (10) : 1068 - +
  • [28] Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial (vol 19, pg 1480, 2018)
    Hodi, F. S.
    Chiarion-Sileni, V
    Gonzalez, R.
    LANCET ONCOLOGY, 2018, 19 (11): : E581 - E581
  • [29] Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial (vol 19, pg 1480, 2018)
    Hodi, F. S.
    Chiarion-Sileni, V
    Gonzalez, R.
    LANCET ONCOLOGY, 2018, 19 (12): : E668 - E668
  • [30] Pilot Trial of Arginine Deprivation Plus Nivolumab and Ipilimumab in Patients with Metastatic Uveal Melanoma
    Kraehenbuehl, Lukas
    Holland, Aliya
    Armstrong, Emma
    O'Shea, Sirinya
    Mangarin, Levi
    Chekalil, Sara
    Johnston, Amanda
    Bomalaski, John S.
    Erinjeri, Joseph P.
    Barker, Christopher A.
    Francis, Jasmine H.
    Wolchok, Jedd D.
    Merghoub, Taha
    Shoushtari, Alexander N.
    CANCERS, 2022, 14 (11)
12345